Full Press Release Details
RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) --BioCryst Pharmaceuticals, Inc.(Nasdaq: BCRX) today announced that the company plans to present at the T.D. Cowen 46thAnnual Health Care Conference in Boston on Tuesday, March 3, 2026, at 9:10 a.m. ET.
The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website atwww.biocryst.com.
About BioCryst PharmaceuticalsBioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO®(berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visitwww.biocryst.comor follow us onLinkedIn.
BCRXW